Silexion Therapeutics LTD (SLXN)
1.13
-0.01 (-0.88%)
At close: Mar 24, 2025, 3:59 PM
1.13
-0.31%
After-hours: Mar 24, 2025, 07:55 PM EDT
-0.88% (1D)
| Bid | 1.11 |
| Market Cap | 9.51M |
| Revenue (ttm) | n/a |
| Net Income (ttm) | n/a |
| EPS (ttm) | -26.36 |
| PE Ratio (ttm) | -0.04 |
| Forward PE | -3.17 |
| Analyst | Buy |
| Ask | 1.14 |
| Volume | 300,607 |
| Avg. Volume (20D) | 14,770,646 |
| Open | 1.12 |
| Previous Close | 1.14 |
| Day's Range | 1.12 - 1.19 |
| 52-Week Range | 0.21 - 13.56 |
| Beta | 0.11 |
About SLXN
Silexion Therapeutics LTD, a biopharmaceutical company, discovers and develops RNA interference (RNAi)-based cancer drugs and delivery systems to treat malignant solid tumors. The company engages in the treatment of solid tumors through its proprietary LODER delivery platform. Its products comprise SiG12D-LODER that has completed pre-clinical studies and an open label Phase I clinical trial for the treatment of pancreatic cancer; Prostate-LODER, ...
Industry Biotechnology
Sector Healthcare
IPO Date Aug 16, 2024
Employees NaN
Stock Exchange NASDAQ
Ticker Symbol SLXN
Website https://silexion.com
Analyst Forecast
According to 1 analyst ratings, the average rating for SLXN stock is "Buy." The 12-month stock price forecast is $5, which is an increase of 342.20% from the latest price.
Stock Forecasts2 weeks ago
+30.63%
Silexion Therapeutics shares are trading higher af...
Unlock content with
Pro Subscription
4 weeks ago
+64%
Silexion therapeutics shares are trading higher after the company announced the completion of its initial study in orthotopic pancreatic cancer models evaluating systemic administration of SIL-204.
